Pharmacogenetics model

Nass R, Miller DM, Blakely RD. 2001. C. elegans A novel pharmacogenetic model to study parkinson s disease. Parkinsonism Relat. Disord. 7 185—91... 

Sorich M, Smith PA, McKinnon RA, Miners JO. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase lAl (UGTIAI) substrates. Pharmacogenetics 2002 12 635-45. 

Weber WW. Acetylation pharmacogenetics experimental models for human toxicity. Fed Proc 1984 43 2332-2337. 

Ratain MJ, Mick R, Janish L et al. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics 1996 6 93-101. 

Cleary, J., Mikus, G., Somogyi, A., Bochner, F. The influence of pharmacogenetics on opioid analgesia studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model, J. Pharmacol. Exp. Ther. 1994, 271, 1528-1534. 

Webster A, Martin P, Lewis G, Smart A. Integrating pharmacogenetics into society In search of a model. Nat Rev Genet 2004 5 663-669. 

Exposure to a ligand (such as TCDD) enhances (i.e., induces) expression of the AhR gene and activates a diverse battery of other genes including CYP1A1. Variability in Ah activity has been studied extensively in animal models, and it is clear that AhR induction by arylhydrocarbons is central to understanding the pharmacogenetics of nuclear receptors (106-108). This topic is more appropriately dealt with in detail elsewhere (see Chapter 2d, Variability of induction processes, A. Okey). 

Welfare MR, Aitkin M, Bassendine MF, Daly AK. Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene lack of a polymorphism in CYP1A2 in Caucasians [published erratum appears in Pharmacogenetics 1999 Dec 9(6) 782]. Pharmacogenetics 1999 9 367-375. 

---